Approaching Antibody Patents After Amgen V. Sanofi
In October of 2017, in Amgen v. Sanofi,[1] the Federal Circuit overturned the "newly characterized antigen" test. This test — which was adopted by the Federal Circuit in 2002, in the...To view the full article, register now.
Already a subscriber? Click here to view full article